Info

🌱 來自: Management- Symptomatic Stages III-IV (or bulky Stage II), Front-line of follicular lymphoma

Rituximab

is a monoclonal Ab directed at ↣ the B-cell Ag CD-20. Efficacy has been shown w/ both single-agent & combination Rx

• Rituximab monotherapy (4 weekly doses) is → used 1° in pts w/ low volume disease. ORR ~70-75%, CR ~40-45% in untreated pts (JCO 2005;23:1103)
• Rituximab plus chemotherapy is → more often used.
  • Standard regimens include
    • R-CHOP,
    • R-Bendamustine,
    • R-CVP.
  • Addition of rituximab to chemotherapy
    • improves RR, PFS, & OS over chemo alone.
  • No single regimen is → preferred, & individual pt factors guide choice

see also: Treatment of systemic lupus erythematosus 󰒖

• ITP, AIHA, refractory SLE
• Infusion reaction / serum sickness, PML, infection